Application 761125
- Type
- BLA
- Sponsor
- NOVARTIS PHARMS CORP
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | BEOVU | brolucizumab-dbll | INJECTABLE; INTRAVITREAL | 6MG/0.05ML | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 0078-0827 | BEOVU | brolucizumab | Novartis Pharmaceuticals Corporation | BLA | Current |
| 0078-0827 | BEOVU | brolucizumab | Novartis Pharmaceuticals Corporation | BLA | Current |
| 0078-0827 | BEOVU | brolucizumab | Novartis Pharmaceuticals Corporation | BLA | Current |
| 0078-0827 | BEOVU | brolucizumab | Novartis Pharmaceuticals Corporation | BLA | Current |
| 0078-0827 | BEOVU | brolucizumab | Novartis Pharmaceuticals Corporation | BLA | Current |
| 0078-0827 | BEOVU | brolucizumab | Novartis Pharmaceuticals Corporation | BLA | Current |
| 0078-0827 | BEOVU | brolucizumab | Novartis Pharmaceuticals Corporation | BLA | Current |
| 0078-0827 | BEOVU | brolucizumab | Novartis Pharmaceuticals Corporation | BLA | Current |
| 0078-0827 | BEOVU | brolucizumab | Novartis Pharmaceuticals Corporation | BLA | Current |